相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models
Claudia Ceci et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Clinical Relevance of the serum CTLA-4 in Cats with Mammary Carcinoma
Ana Catarina Urbano et al.
SCIENTIFIC REPORTS (2020)
Expression of HIF-1α and VEGF in feline mammary gland carcinomas: association with pathological characteristics and clinical outcomes
Bo Chen et al.
BMC VETERINARY RESEARCH (2020)
Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes
Catarina Nascimento et al.
CANCERS (2020)
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
Josep Garcia et al.
CANCER TREATMENT REVIEWS (2020)
Neuropilins, as Relevant Oncology Target: Their Role in the Tumoral Microenvironment
Aurore Dumond et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer
Takaaki Fujii et al.
IN VIVO (2020)
Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival
Ruo-Xi Wang et al.
ONCOLOGIST (2019)
Contribution of Angiogenesis to Inflammation and Cancer
Dolores Aguilar-Cazares et al.
FRONTIERS IN ONCOLOGY (2019)
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial
Giuseppe Gullo et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer
Kristina Golfmann et al.
ONCOGENE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Plasma levels of VEGF-A, VEGF B, and VEGFR-1 and applicability of these parameters as tumor markers in diagnosis of breast cancer
Monika Zajkowska et al.
ACTA BIOCHIMICA POLONICA (2018)
Serum levels of VEGF and MCSF in HER2+/HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
Roberto J. Arai et al.
BIOMARKER RESEARCH (2018)
High VEGFR1/2 expression levels are predictors of poor survival in patients with cervical cancer
Yun-Zhi Dang et al.
MEDICINE (2017)
St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study
M. Soares et al.
TUMOR BIOLOGY (2016)
Ki-67 as a Prognostic Factor in Feline Mammary Carcinoma: What Is the Optimal Cutoff Value?
M. Soares et al.
VETERINARY PATHOLOGY (2016)
Molecular based subtyping of feline mammary carcinomas and clinicopathological characterization
Maria Soares et al.
BREAST (2016)
Anti-tumor effect of bevacizumab on a xenograft model of feline mammary carcinoma
Masaki Michishita et al.
JOURNAL OF VETERINARY MEDICAL SCIENCE (2016)
Mechanisms and regulation of endothelial VEGF receptor signalling
Michael Simons et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way
Nuket Eliyatkin et al.
JOURNAL OF BREAST HEALTH (2015)
Serum VEGF levels and tissue activation of VEGFR2/KDR receptors in patients with breast and gynecologic cancer
Michael I. Koukourakis et al.
CYTOKINE (2011)
Elevated serum and tissue VEGF associated with poor outcome in breast cancer patients
Enas Mohamed Ali et al.
ALEXANDRIA JOURNAL OF MEDICINE (2011)
The role of VEGF in triple-negative breast cancer: where do we go from here?
S. F. Dent
ANNALS OF ONCOLOGY (2009)
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
B. K. Linderholm et al.
ANNALS OF ONCOLOGY (2009)
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer
C. Kut et al.
BRITISH JOURNAL OF CANCER (2007)
Vascular endothelial growth factor and its relationship to inflammatory mediators
Laura S. Angelo et al.
CLINICAL CANCER RESEARCH (2007)
Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells
S Garvin et al.
BRITISH JOURNAL OF CANCER (2005)
Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the α5β1 integrin
A Orecchia et al.
JOURNAL OF CELL SCIENCE (2003)
Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer
M Toi et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
分享论文
